Total Funding
1
30
Total FundingVenture - Series Unknown raised
Growth Score
-26 pts
Heat Score
2 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
See more interactive data and historical milestones on desktop for the best experience
59144
Canopy Biosciences aims to accelerate the commercialization of life science reagent tools and services through in-licensing.
Julie Leaderbrand: Product Marketing ManagerPast Role: Merck, Marketing Communications Manager
Crystal Winkeler: Co-Founder & COOPast Role: BioGenerator, Investment Analyst
About the Company
Canopy Biosciences is biotechnological company that provides products and services for gene editing and personalized medicine. The gene editing technology is called TUNR and targets translation elongation by inserting polyA tracks into targeted coding regions of the genome. This change then decreases the levels of mRNA transcribed from the gene and
therefore suppresses protein expression. It was initially developed by Professor Sergej Djuranovic at Washington University School of Medicine and Professor Rachel Green from Johns Hopkins University.
Canopy Biosciences was formed in 2016 and is headquartered in Saint Louis, Missouri.
Women Founded
